Biocon Unit Secures Japan Approval for Pegfilgrastim Biosimilar

BENGALURU — Biocon Biologics Ltd., a wholly-owned subsidiary of biotechnology major Biocon Ltd. (BSE: 532523, NSE: BIOCON), has secured marketing approval for its pegfilgrastim biosimilar from Japan’s Ministry of Health, Labour and Welfare (MHLW).

The regulatory approval, confirmed on Tuesday, August 25, 2026, grants commercial access for the therapeutic product in one of Asia's largest pharmaceutical markets. Developed and manufactured by Biocon Biologics Ltd., the product serves as a biosimilar to Neulasta® (a registered trademark of Amgen Inc.), which is prescribed to manage bone marrow suppression and reduce infection risks in cancer patients undergoing chemotherapy.

Commercialization Structure and Regulatory Holders

Under the approved regulatory framework, Global Regulatory Partners Japan will act as the Marketing Authorization Holder (MAH) in Japan on behalf of Biocon. Commercial execution will be managed by Sandoz K.K., which has secured exclusive rights to promote, distribute, and sell the pegfilgrastim biosimilar across Japanese healthcare networks.

The strategic arrangement leverages Sandoz's commercial footprint in Japan while allowing Biocon Biologics to expand its global biosimilar portfolio across advanced economies.

Strategic Impact on Global Biosimilar Expansion

The authorization reinforces Biocon’s focus on scaling its advanced oncology and biosimilar footprint in highly regulated international markets. The company has consistently pursued registration and commercial expansion across North America, Europe, and Asia-Pacific to broaden access to high-quality biological therapies.

The clearance from Japan's MHLW enhances Biocon’s commercial pipeline while strengthening its position in the specialized oncology segment.

Official Sources Section

Regulatory approvals and corporate filings were submitted directly to market regulators and public portals:

• Official regulatory disclosure filed with the BSE Limited

• Disclosure filing submitted to the National Stock Exchange of India (NSE)

• Official statement published by Biocon Limited

• Regulatory health updates monitored via the Ministry of Health, Labour and Welfare (MHLW) Japan

Quote Section

"This approval further strengthens Biocon's portfolio of biosimilar products in Japan and reaffirms the company's commitment to increasing patient access to high-quality and affordable medications globally," stated a spokesperson for Biocon.

Why It Matters

Japan represents one of the world's largest pharmaceutical and biosimilar markets with strict regulatory evaluation standards. Gaining MHLW authorization enables Biocon Biologics to generate new revenue streams in Asia-Pacific while providing oncology patients and healthcare providers in Japan with an alternative therapeutic option for chemotherapy-induced neutropenia.

Key Facts at a Glance

• Regulatory Approval: Approved by Japan's MHLW on August 25, 2026.

• Reference Drug: Biosimilar to Amgen’s Neulasta® (pegfilgrastim).

• Exclusive Distributor: Sandoz K.K. holds exclusive promotion and sales rights in Japan.

• Regulatory Holder: Global Regulatory Partners Japan serves as the Marketing Authorization Holder.

Frequently Asked Questions (FAQ)

What is the pegfilgrastim biosimilar approved in Japan?

It is a biopharmaceutical product developed by Biocon Biologics Ltd. that is biosimilar to Neulasta® (pegfilgrastim), used primarily to treat neutropenia caused by cancer chemotherapy.

Who will sell Biocon's pegfilgrastim biosimilar in Japan?

Sandoz K.K. has acquired exclusive rights to market, promote, distribute, and sell the pegfilgrastim biosimilar in Japan.

Which authority approved the drug?

Japan’s Ministry of Health, Labour and Welfare (MHLW) granted the marketing authorization.

Source: Biocon Limited Corporate Filings, BSE Limited, National Stock Exchange of India (NSE), Ministry of Health, Labour and Welfare (MHLW) Japan.